数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
研究问题
Parkinson’s disease (PD) is a progressive neurodegenerative condition primarily marked by the targeted loss of dopaminergic neurons in the substantia nigra pars compacta.
方法
In parallel, activation of microglia and the subsequent release of pro-inflammatory mediators, including IL-1β, IL-6, TNF-α, and COX-2-associated mediators, can further enhance ROS generation and neuronal injury [29].；The selected systems included PDB ID: 1GOS complexed with Scytonemin, Calothrixin B and Zeaxanthin.
核心结论
The prediction showed an average structural similarity of 70.82% and a prediction accuracy of 69.26%, suggesting a moderate-to-good confidence level in the computational estimation.；However, its Protox 3 prediction was associated with a relatively lower average similarity 46.28% and prediction accuracy 54.26%, indicating that the predicted toxicity should be interpreted with greater caution.；Nevertheless, Zeaxanthin showed a relatively high average similarity (82.54%) and prediction accuracy (70.97%), providing comparatively stronger computational support for the prediction. ‖ 结论：The present study employed an integrative in silico approach to identify potential MAO-B-interacting compounds from cyanobacteria relevant to Parkinson’s disease.
局限
全文未设独立 limitations 节；结构上为非 RCT 设计，因果推断强度受限。
对本项目的价值
★★☆☆☆ 脑老化是最大未满足需求，也是终点最难量化的领域；biomarker 与认知读数选择最敏感。
全文来源
PMC JATS 全文（正文 44,649 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：In Silico Evaluation of Cyanobacteria-Derived Bioactive Compounds as Potential Monoamine Oxidase-B Inhibitors for Parkinson's Disease: Molecular Docking and Molecular Dynamics Simulation Study.
- 期刊与标识：Pharmaceuticals (Basel) · PMID 42943266 · DOI 10.3390/ph19101569**
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。